Hyperthermic isolated perfusion with low-dose TNFα and doxorubicin in patients with locally advanced soft tissue limb sarcomas

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 5, 2004, Pages 58-61

  Rossi, Carlo Ricardo ^a   Foletto, M ^a   Mocellin, S ^a   Pilati, P ^a   Quintieri, L ^a   De Salvo, G L ^b   Nitti, D ^a   Lise, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Regional Cancer Centre   (Italy)

Author keywords

Doxorubicin; Isolated limb perfusion; Locally advanced soft tissue limb sarcomas; TNF

Indexed keywords

ANALGESIC AGENT; DOXORUBICIN; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT SYNDROME; CONFERENCE PAPER; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTHERMIC ISOLATED LIMB PERFUSION; HYPERTHERMIC THERAPY; LIMB DISEASE; LIMB PERFUSION; LIMB SALVAGE; LIMB TUMOR; LOW DRUG DOSE; MALE; NEURALGIA; PERONEUS NERVE PARALYSIS; PHASE 2 CLINICAL TRIAL; SOFT TISSUE SARCOMA; SYSTEMIC DISEASE; TUMOR LOCALIZATION;

EID: 11144248849     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2004.11782387     Document Type: Conference Paper

References (12)

1. Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J Immunother 2003;26:291-300.
2. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
3. Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405-12.
4. Di Filippo F, Rossi CR, Vaglini M, et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999;22:407-14.
5. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuuant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-6.
6. Casara D, Rubello D, Pilati P. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion cancer therapy. Eur J Nuclear Med 2001;28:1174.
7. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
8. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995-7.
9. Watanabe N, Niitsu Y, Umeno H. et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988;48:650-3.
10. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF- alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973-80.
11. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64; discussion 764-5.
12. rd Expert Meeting Beromun, 2003 October 3-4; Madrid.